Abstract
Various human tumors preferentially metastasize by lymphatic route and lymphovascular invasion predicts lymph node metastasis. In this review article, we will summarize recent literature data concerning lymphangiogenesis, focusing on tumor lymphangiogenesis. In detail, we try to answer some important questions related to: a) The specificity of lymphatic endothelial cell markers; b) The differential characteristics of lymphatic vessels in tumors; c) The interplay between different lymphangiogenic factors; d) The role of pre-existing and newly-formed lymphatic vessels in tumors and their proliferative potential; e) The role of lymphatic vessels in tumor metastases; e) The prognostic significance of lymphatic microvascular density in tumors; f) The inhibition of lymphangiogenesis in tumors.
Keywords: Lymphangiogenesis, lymphatic endothelial cell, lymphatic microvascular density, metastases, tumor progression, vascular endothelial growth factor
Current Medicinal Chemistry
Title: Targeting Tumor Lymphangiogenesis: An Update
Volume: 17 Issue: 8
Author(s): M. Raica and D. Ribatti
Affiliation:
Keywords: Lymphangiogenesis, lymphatic endothelial cell, lymphatic microvascular density, metastases, tumor progression, vascular endothelial growth factor
Abstract: Various human tumors preferentially metastasize by lymphatic route and lymphovascular invasion predicts lymph node metastasis. In this review article, we will summarize recent literature data concerning lymphangiogenesis, focusing on tumor lymphangiogenesis. In detail, we try to answer some important questions related to: a) The specificity of lymphatic endothelial cell markers; b) The differential characteristics of lymphatic vessels in tumors; c) The interplay between different lymphangiogenic factors; d) The role of pre-existing and newly-formed lymphatic vessels in tumors and their proliferative potential; e) The role of lymphatic vessels in tumor metastases; e) The prognostic significance of lymphatic microvascular density in tumors; f) The inhibition of lymphangiogenesis in tumors.
Export Options
About this article
Cite this article as:
Raica M. and Ribatti D., Targeting Tumor Lymphangiogenesis: An Update, Current Medicinal Chemistry 2010; 17 (8) . https://dx.doi.org/10.2174/092986710790514471
DOI https://dx.doi.org/10.2174/092986710790514471 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide
Current Cancer Drug Targets Recent Advances in Treatment Approaches to Gaucher Disease
Current Pharmaceutical Biotechnology Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma
Current Cancer Drug Targets The Significance of Ubiquitin Proteasome Pathway in Cancer Development
Recent Patents on Anti-Cancer Drug Discovery Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Current Cancer Therapy Reviews Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
Current Cancer Drug Targets Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets Histopathological Determinants of Tumor Resistance: A Special Look to the Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers
Current Medicinal Chemistry Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Current Pharmaceutical Design Ketamine for Chronic Pain and Treatment Resistant Depression: A Mechanistic Hypothesis
Current Drug Therapy Multifunctional Radiolabeled Nanoparticles for Targeted Therapy
Current Medicinal Chemistry Advances and Perspectives in Cancer Nanotherapy: The Added- Value of Nanocarriers
Current Nanomedicine New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies
Current Medicinal Chemistry Carbon Nanotubes in the Diagnosis and Treatment of Malignant Melanoma
Anti-Cancer Agents in Medicinal Chemistry The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry